Effect of prior therapy with nilotinib or dasatinib on the outcome after allogeneic stem cell transplantation for patients with chronic myeloid leukaemia

被引：0
|
作者：
Schleuning, M.
Scholten, M.
van Biezen, A.
Nagler, A.
Apperley, J.
Michallet, M.
Grigg, A.
Silver, R.
Niederwieser, D.
De Witte, T.
Olavarria, E.
机构：
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [31] The impact of second generation tyrosine kinase inhibitors on the outcome of allogeneic stem cell transplantation for chronic myeloid leukaemia
    Latif, A.
    Parker, A.
    McQuaker, G.
    Clark, A.
    Copland, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 23 - 24
  • [32] The Negative Impact of Imatinib Mesylate Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia
    Al-Anazi, K. A.
    Chaudhri, N.
    Al-Mohareb, F. I.
    Al-Zahrani, H. A.
    Al-Omar, H. M.
    Al-Shanqeeti, A.
    Sahovic, E.
    Al Sharif, F. Z.
    Mohamed, S. Y.
    Rasheed, W.
    Beihani, A.
    Hejazi, A.
    Zaidi, Z.
    Morshid, M.
    Seth, P.
    El-Tayeb, K. I.
    Nassar, A.
    Bakr, M.
    Abu Jafar, S.
    Othman, I. A.
    Abdulwahab, A.
    Al-Sultan, O.
    Aljurf, M. D.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 877 - 888
  • [33] The quality of molecular remission after stem cell transplantation in patients with chronic myeloid leukaemia
    Lewandowski, K.
    Gil, L.
    Baranska, M.
    Iwola, M.
    Drozdowska, D.
    Lewandowska, M.
    Komarnicki, M.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S317 - S317
  • [34] Haematopoietic stem cell transplantation for patients with chronic myeloid leukaemia after failure of tyrosine kinase inhibitor therapy
    Prayongratana, K.
    Forrest, D.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S428 - S429
  • [35] Imatinib mesylate treatment of patients with chronic myeloid leukaemia relapsing following allogeneic stem cell transplantation
    Conneally, E
    Carroll, P
    Neat, M
    Haslam, K
    Gately, K
    Ryan, J
    Lawler, M
    McCann, S
    BLOOD, 2004, 104 (11) : 248B - 249B
  • [36] Allogeneic haemotopoietic stem cell transplantation outcomes in imatinib-treated chronic myeloid leukaemia patients
    Ahn, H. K.
    Jung, C. W.
    Kim, K.
    Jang, J. H.
    Kim, D. H.
    Yoon, S. S.
    Kim, I. H.
    Sohn, S. K.
    Moon, J. H.
    Lee, J. H.
    Lee, K. H.
    Won, J. H.
    Lee, N. S.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S244 - S244
  • [37] Allogeneic stem cell transplantation in patients with chronic myeloid leukaemia: application of the EBMT risk scoring system
    Novella, E
    Madeo, D
    Raimondi, R
    Cappellari, A
    Guercini, N
    Montaldi, AM
    Roberti, S
    Rodeghiero, F
    BONE MARROW TRANSPLANTATION, 2005, 35 : S235 - S235
  • [38] Outcome and prognostic factors in patients with relapse of acute leukaemia after allogeneic stem cell transplantation
    Heiwa, K.
    Kenji, M.
    Eriko, O.
    Wataru, Y.
    Yoshiaki, I.
    Atsuo, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S249 - S249
  • [39] Development of donor cell derived acute myeloid leukaemia after stem cell transplantation for chronic myeloid leukaemia
    Pieroni, F
    Oliveira, FM
    Moraes, D
    Straccieri, ABPL
    Rodrigues, MC
    Panepucci, RA
    Voltarelli, JC
    Simoes, BP
    Falcao, RP
    BONE MARROW TRANSPLANTATION, 2006, 37 : S219 - S220
  • [40] Allogeneic haematopoietic stem cell transplantation for patients with chronic lymphocytic leukaemia
    Zaucha, J. M.
    Bieniaszewska, M.
    Piekarska, A.
    Prejzner, W.
    Knopinska-Posluszny, W.
    Hellmann, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S316 - S316
12345